RE:All comersI did mention some time ago that Thera would do a test on the tumors to look for overexpression of Sort1. About a year ago, I had that discussion with Christian about if a tumor achive sample could be used instead of a biopsy. He said back then archival sample would be fine.
I would believe that with these late stage cancer patients changes would be good that at least some would be over expressing Sort1.
SPCEO1 wrote: THTX as noted several times that the phase 1a will take anyone who meets their criteria for the trial. I am not sure if we new this already or not but Paul told a friend of mine that they will be checking the patients tumors after the test to determine if they were overexpressing sortilin. So, with a small number of patients involved, there is a chance that none of those accepted into the trial will have sortilin overexpressing tumors. Now, I have to believe the chances are still pretty good that some will have sortilin overexpressing tumors but there are no guarantees since they are not pre-screening patients to admit an assortment of expressing and non-expressing patients into the trial.
He also said that Dr, Rothenberg had done a deep dive into TH's science before joining and that he would be helpful in reducing risk in their clinical development and creating multiple pathway to win. I think it is important that Dr. Rothenberg joined because of the science and not because he and Paul were fishing buddies from their time together at Pfizer.